Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

696 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Aromatization inhibition alone or in combination with GnRH agonists for the treatment of premenopausal breast cancer patients.
Dowsett M, Stein RC, Coombes RC. Dowsett M, et al. J Steroid Biochem Mol Biol. 1992 Sep;43(1-3):155-9. doi: 10.1016/0960-0760(92)90201-s. J Steroid Biochem Mol Biol. 1992. PMID: 1388047 Review.
We found that the more potent inhibitor, 4-hydroxyandrostenedione (4-OHA), which can suppress oestrogen synthesis in rodents and non-human primates with intact ovarian function, was also unsuccessful as an oestrogen suppressant in premenopausal women at its maximum tolerated dose …
We found that the more potent inhibitor, 4-hydroxyandrostenedione (4-OHA), which can suppress oestrogen synthesis in rodents and non-human p …
The influence of aminoglutethimide and its analogue rogletimide on peripheral aromatisation in breast cancer.
MacNeill FA, Jones AL, Jacobs S, Lønning PE, Powles TJ, Dowsett M. MacNeill FA, et al. Br J Cancer. 1992 Oct;66(4):692-7. doi: 10.1038/bjc.1992.339. Br J Cancer. 1992. PMID: 1419608 Free PMC article.
AG mean aromatase inhibition was 90.6% +/- 1.8 s.e.m. and E2 suppression 75.7% +/- 7.3 s.e.m. RG mean aromatase inhibition was 50.6% +/- 9.8 s.e.m. at 200 mg bd, 63.5% +/- 5.7 s.e.m. at 400 mg bd and 73.8% +/- 5.8 s.e.m. at 800 mg bd. E2 suppres …
AG mean aromatase inhibition was 90.6% +/- 1.8 s.e.m. and E2 suppression 75.7% +/- 7.3 s.e.m. RG mean aromatase inhibition was …
Influence of aminoglutethimide on plasma oestrogen levels in breast cancer patients on 4-hydroxyandrostenedione treatment.
Lønning PE, Dowsett M, Jones A, Ekse D, Jacobs S, McNeil F, Johannessen DC, Powles TJ. Lønning PE, et al. Breast Cancer Res Treat. 1992;23(1-2):57-62. doi: 10.1007/BF01831476. Breast Cancer Res Treat. 1992. PMID: 1446052 Clinical Trial.
Towards a molecular basis for tamoxifen resistance in breast cancer.
Johnston SR, Dowsett M, Smith IE. Johnston SR, et al. Ann Oncol. 1992 Jul;3(7):503-11. doi: 10.1093/oxfordjournals.annonc.a058251. Ann Oncol. 1992. PMID: 1498070 Review.
696 results
Jump to page
Feedback